Sabina Rak

Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Two grass pollen tablets commercially available for allergy immunotherapy display different IgE epitope repertoires.

Two grass pollen tablets commercially available for allergy immunotherapy display different IgE epitope repertoires.

Journal: Clinical and translational allergy

Published: October 26, 2018

Efficacy and safety of birch pollen allergoid subcutaneous immunotherapy: A 2-year double-blind, placebo-controlled, randomized trial plus 1-year open-label extension.

Efficacy and safety of birch pollen allergoid subcutaneous immunotherapy: A 2-year double-blind, placebo-controlled, randomized trial plus 1-year open-label extension.

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Published: April 03, 2018

Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients.

Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients.

Journal: Allergy

Published: March 27, 2015

Characterization of oral immune cells in birch pollen-allergic patients: impact of the oral allergy syndrome and sublingual allergen immunotherapy on antigen-presenting cells.

Characterization of oral immune cells in birch pollen-allergic patients: impact of the oral allergy syndrome and sublingual allergen immunotherapy on antigen-presenting cells.

Journal: Allergy

Published: January 19, 2015

Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper.

Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper.

Journal: Allergy

Published: February 02, 2014

Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study.

Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study.

Journal: Clinical and translational allergy

Published: November 29, 2013

EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy.

EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy.

Journal: Clinical and translational allergy

Published: September 24, 2012

Anti-apoptotic BFL-1 is the major effector in activation-induced human mast cell survival.

Anti-apoptotic BFL-1 is the major effector in activation-induced human mast cell survival.

Journal: PloS one

Published: November 01, 2011

Showing 1-8 of 8

Last Updated: 09/26/2026